In Brief: Lilly's lispro insulin analog

Lilly's lispro insulin analog: NDA sent to FDA March 13 for lispro, tradenamed Humalog, as an injectable treatment for Type I diabetes. The NDA is based on data from more than 3,000 patients worldwide. Studies presented at the International Diabetes Federation Conference in November in Kobe, Japan show that "lispro injected immediately before the meal results in improved postprandial glucose control in comparison to" human regular insulin "given at least 30 minutes before the meal," according to an abstract of a 336-patient study...